Elexacaftor/tezacaftor/ivacaftor use is linked to long-term decreases in chronic respiratory therapies in patients with cystic fibrosis.
In the US, nearly one third of eligible lung transplant recipients with cystic fibrosis (CF) received new elexacaftor-tezacaftor-ivacaftor (ETI) prescriptions post-transplant. The presence of sinus ...
ETI (ETI) has delivered a 63.93% change over the past year, with a 52-week range between 23.50 and 46.00. What Is the Average Daily Trading Volume of ETI (ETI)? The average daily trading volume for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback